Clinical Trial Update: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating LXI-15028 for non-erosive reflux disease in Chinese patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-erosive Reflux Disease

Drugs mentioned

• LXI-15028

Snippet

Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Conditions: Non-erosive Reflux Disease | Phase 3 | Status: COMPLETED